What is Memphasys?
Memphasys Limited is at the forefront of reproductive biotechnology, specializing in the development and commercialization of the proprietary Felix System. This advanced technology is engineered to isolate the most viable sperm cells, a critical step in human assisted reproductive technology (ART) procedures. With CE Mark certification, the Felix System is actively used in fertility clinics internationally, including key markets in Europe, Australia, the Middle East, Japan, and New Zealand. The company's strategic focus is on advancing artificial reproduction and fertility solutions, driven by ongoing research and development collaborations with leading experts in the field.
How much funding has Memphasys raised?
Memphasys has raised a total of $3M across 1 funding round:
Other Financing Round
$3M
Other Financing Round (2021): $3M with participation from Peter Investments and Andrew Goodall
Key Investors in Memphasys
Peter Investments
Peter Investments is an entity that participated in Memphasys's funding round. Further details on their investment focus are not publicly available.
Andrew Goodall
Andrew Goodall is an individual investor who contributed to Memphasys's recent financing. Specific investment preferences are undisclosed.
What's next for Memphasys?
The recent major strategic investment provides Memphasys with substantial backing to further its mission of enhancing fertility technologies. This capital infusion is expected to fuel expanded market presence and accelerate the development of next-generation artificial reproduction solutions. As a company operating in the enterprise-level funding landscape, Memphasys is poised to deepen its research initiatives and potentially forge new strategic partnerships to solidify its position in the global fertility market. The company's trajectory suggests a continued focus on innovation and market penetration within the ART sector.
See full Memphasys company page
